Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | MAOA | P21397 | 4/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9550369 | 0.87 | FLT3 (0.52) | MAOBMAOAADORA3ADORA1ADORA2A | |
| SCHEMBL10648590 | 0.86 | LMNA (0.64) | MAOBMAOAADORA3ADORA1ADORA2A | |
| SCHEMBL2681830 | 0.84 | ALDH1A1 (0.65) | MAOBMAOAADORA3ADORA1ADORA2A | |
| SCHEMBL4508415 | 0.84 | MAOB (0.47) | MAOBMAOAADORA3ADORA1ADORA2A | |
| SCHEMBL2010000 | 0.81 | MAOA (0.62) | MAOBMAOAADORA3ADORA1ADORA2A | |
| SCHEMBL3076627 | 0.81 | LMNA (0.51) | MAOBMAOAADORA3ADORA1ADORA2A | |
| SCHEMBL6239922 | 0.80 | RAB9A (0.50) | MAOBMAOAADORA3ADORA1ADORA2A | |
| SCHEMBL17724009 | 0.80 | MAOA (0.51) | MAOBMAOALMNARECQLKMT2A | |
| SCHEMBL25300447 | 0.79 | LMNA (0.45) | MAOALMNARECQLKMT2AMEN1 | |
| SCHEMBL29503553 | 0.79 | LMNA (0.45) | MAOALMNARECQLKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4329881-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | Vanqua Bio, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117642404-A | Small molecule modulators of glucocerebrosidase activity and uses thereof | 凡况生化公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| WO-2022232383-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20220324800-A1 | SARS-3CL PROTEASE INHIBITORS | Primmune Therapeutics, Inc. | 2022-10-13 | — | — | US | disclosed |
| WO-2022212707-A1 | SARS-3CL PROTEASE INHIBITORS | Primmune Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
| CN-107151255-A | Boric acid compound and its production and use | 复旦大学 | 2017-09-12 | — | — | CN | disclosed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
| EP-1320523-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| EP-1320523-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002024672-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-0029311-B1 | AMINOALKYL BENZOFURAN DERIVATIVES, THEIR PRODUCTION AND COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1985-01-23 | — | — | EP | disclosed |
| EP-0029311-A1 | Aminoalkyl benzofuran derivatives, their production and compositions containing them | MERCK & CO. INC. (US) | 1981-05-27 | — | — | EP | disclosed |
| US-4238487-A | ANTISECRETORY AGENTS | MERCK & CO., INC. (US) | 1980-12-09 | — | — | US | disclosed |
| US-4009994-A | Process and product of optical brightening with quaternized benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1977-03-01 | — | — | US | disclosed |
| US-3940417-A | Quaternised benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | MAOB 863/4885MAOA 810/4885ADORA3 3350/4885 |
| US-20220324800-A1 | SARS-3CL PROTEASE INHIBITORS | ACE, ACE2, SARS1 | MAOB 2301/4885MAOA 2410/4885ADORA3 3693/4885 |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | MAOB 2841/4885MAOA 2773/4885ADORA3 4199/4885 |
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | MAOB 202/4885MAOA 299/4885ADORA3 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.